Abstract:Introduction: Subcritical epileptiform activity is associated with impaired cognitive function and is commonly seen in patients with Alzheimer's disease (AD). The anti-convulsant, levetiracetam (LEV), is currently being evaluated in clinical trials for its ability to reduce epileptiform activity and improve cognitive function in AD. The purpose of the current study was to apply pharmacokinetics (PK), network analysis of medical imaging, gene transcriptomics, and PK/PD modeling to a cohort of amyloidogenic mice to establish how LEV restores or drives alterations in the brain networks of mice in a dose-dependent basis using the rigorous preclinical pipeline of the MODEL-AD Preclinical Testing Core. Methods: Chronic LEV was administered to 5XFAD mice of both sexes for 3 months based on allometrically scaled clinical dose levels from PK models. Data collection and analysis consisted of a multi-modal approach utilizing 18 F-FDG PET/MRI imaging and analysis, transcriptomic analyses, and PK/PD modeling. Results: Pharmacokinetics of LEV showed a sex and dose dependence in C max , CL/F, and AUC 0-∞ , with simulations used to estimate dose regimens. Chronic dosing at 10, 30, and 56 mg/kg, showed 18 F-FDG specific regional differences in brain uptake, and in whole brain covariance measures such as clustering coefficient, degree, network density, and connection strength (i.e., positive and negative). In addition, transcriptomic analysis via nanoString showed dose-dependent changes in gene expression in pathways consistent 18 F-FDG uptake and network changes, and PK/PD modeling showed a concentration dependence for key genes, but not for network covariance modeling. Discussion: This study represents the first report detailing the relationships of metabolic covariance and transcriptomic network changes resulting from LEV administration in 5XFAD mice. Overall, our results highlight non-linear kinetics based on dose and sex, where gene expression analysis demonstrated LEV dose- and concentration-dependent changes, along with cerebral metabolism, and/or cerebral homeostatic mechanisms relevant to human AD, which aligned closely with network covariance analysis of 18 F-FDG images. Collectively, this study show cases the value of a multimodal connectomic, transcriptomic, and pharmacokinetic approach to further investigate dose dependent relationships in preclinical studies, with translational value toward informing clinical study design.

Levetiracetam promoted rat embryonic neurogenesis via NMDA receptor-mediated mechanism in vitro

A Randomized Controlled Trial Measuring Changes in Cerebral Blood Flow after Levetiracetam in Patients with Alzheimer’s Disease

The Regulative Effects of Levetiracetam on Adult Hippocampal Neurogenesis in Mice Via Wnt/β-catenin Signaling

Oligoprotective Activity of Levetiracetam Against Glutamate Toxicity: An in vitro Study

Levetiracetam Protects Against Cognitive Impairment Of Subthreshold Convulsant Discharge Model Rats By Activating Protein Kinase C (Pkc)-Growth-Associated Protein 43 (Gap-43)-Calmodulin-Dependent Protein Kinase (Camk) Signal Transduction Pathway

Real-Time Monitoring of Levetiracetam Effect on the Electrophysiology of an Heterogenous Human iPSC-Derived Neuronal Cell Culture Using Microelectrode Array Technology

Effect of intranasal and oral administration of levetiracetam on the temporal and spatial distributions of SV2A in the KA‐induced rat model of SE

Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes

Levetiracetam inhibits endocytosis and augments short-term depression

Levetiracetam modulates brain metabolic networks and transcriptomic signatures in the 5XFAD mouse model of Alzheimer's disease

Morphological and histopathological changes of maternal levetiracetam on the cerebellar cortex of the offspring of albino rat

Modulation of action potential and calcium signaling by levetiracetam in rat sensory neurons

Levetiracetam for Epilepsy: an Evidence Map of Efficacy, Safety and Economic Profiles.

Levetiracetam Administration is Correlated with Lower Mortality in Patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes: a Retrospective Study

Evaluation of levetiracetam on the gray matter structure remodeling in benign epilepsy children with-central temporal spikes

Single-dose Intravenous Administration of Antiepileptic Drugs Induces Rapid and Reversible Remodeling in the Brain: Evidence from a Voxel-Based Morphometry Evaluation of Valproate and Levetiracetam in Rhesus Monkeys

Impact of levetiracetam on cognitive impairment, neuroinflammation, oxidative stress, and neuronal apoptosis caused by lipopolysaccharides in rats

VEGF Modulates Neurogenesis and Microvascular Remodeling in Epileptogenesis After Status Epilepticus in Immature Rats

[Effect of Levetiracetam on the Sodium Currents of Rat Hippocampal Neurons Exposed to Coriaria Lactone].

Levetiracetam Ameliorates Doxorubicin-Induced Chemobrain by Enhancing Cholinergic Transmission and Reducing Neuroinflammation Using an Experimental Rat Model and Molecular Docking Study

Changes in the Dentate Gyrus Gene Expression Profile Induced by Levetiracetam Treatment in Rats with Mesial Temporal Lobe Epilepsy